Dan Becker
Biotech Investor at Access Biotechnology
New York, New York
Skills
Education
Work Experience
2019
Managing Director, Access Biotechnology
2019
Biopharma investing in private and public companies across therapeutic areas, modalities, and development stages. Representative private investments include Nimbus Therapeutics (Tyk2 subsidiary acq. by Takeda for up to $6 billion incl. $4 billion upfront), Hemab, Areteia Therapeutics, Perfuse Therapeutics, and Matchpoint Therapeutics www.accessbiotech.com
Board Member
2025
2022 - 2025
Board Member
2022 - 2025
IPO May 2023 (NASDAQ: SLRN); merged with Alumis Inc, (NASDAQ: ALMS) in May 2025
2021 - 2024
Board Member
2021 - 2024
Co-founding investor; acquired by Novartis for up to $1.75 billion including $1 billion upfront
2019 - 2024
Board Member
2019 - 2024
IPO May 2021 (NASDAQ: DAWN)
2021 - 2023
Board Member
2021 - 2023
Acquired by Novartis for up to $1 billion including $0.5 billion upfront
2020 - 2021
Board Member
2020 - 2021
IPO July 2020 (NASDAQ: PAND); Acquired by Merck for $1.85 billion April 2021
2017 - 2020
Board Member
2017 - 2020
IPO Sept. 2018 (NASDAQ: PRNB); Acquired by Sanofi for $3.7 billion Sept. 2020
2015 - 2019
Principal
2015 - 2019
2009 - 2015
Principal
2009 - 2015
Core member of Health Care practice, with emphasis on pharma R&D and experience across multiple subsectors. Selected for Ambassador program, transferred to London office during 2012.